At the news
? BULLISHIMPACT 8/10 8-K filed Jun 9, 2026 at 07:03 ET
GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion. The transaction includes two late-stage ROS1 and ALK inhibitors (zidesamtinib and neladalkib) under FDA review with 2026 target action dates, plus a phase I HER2 inhibitor. Stockholders representing ~28% of Class A shares have signed tender and support agreements to tender their shares. The deal is expected to close in Q3 2026, subject to regulatory approval and a majority-of-shares tender condition.
- GSK to acquire Nuvalent for $124.00 per share in cash, aggregate equity value of $10.6 billion
- Purchase price represents a 40% premium to last closing price and a 26% premium to 30-day VWAP
- Two late-stage assets (zidesamtinib for ROS1+ NSCLC, neladalkib for ALK+ NSCLC) under FDA review with PDUFA dates of Sept 18, 2026 and Nov 27, 2026
- Third asset NVL-330 (HER2 inhibitor) in phase I for HER2-altered NSCLC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access